22nd Century Announces $40 Million Common Stock Registered Direct Offering
BUFFALO, N.Y., June 07, 2021 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based biotechnology company focused
Read more
Smokless Tobacco
CV Sciences, Inc. Receives Notice of Patent Allowance from USPTO for Proprietary Cannabidiol (CBD) and Nicotine Formulation for Treating Smokeless Tobacco Addiction
SAN DIEGO, April 06, 2020 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent
Read more